TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3125575

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both substances
Number of subjects: 0
Study: 29525494

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 0
Study: 27487342

Group type: EXPERIMENTAL
Intervention: PTH‐1‐37 (10 µg, 20 µg, 40 µg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PTH‐1‐34 (20 µg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 24072523

Group type: EXPERIMENTAL
Intervention: Preventive support groups
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study: 22189004

Group type: EXPERIMENTAL
Intervention: Dietary counseling during 10 home visits
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding up to 6 months
Number of subjects: 397
Study: 20569506

Group type: EXPERIMENTAL
Intervention: High-fat diet rich in SFA
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: High-fat diet rich in MUFA
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Low-fat high-complex carbohydrate diet with n-3 supplementation (LFHCC n-3)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Low-fat high-complex carbohydrate diet without n-3 supplementation (LFHCC)
Number of subjects: 417

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 417
Study: 18477897

Group type: EXPERIMENTAL
Intervention: Adjuvant intra-arterial hepatic fotemustine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (3:1 matched control group)
Number of subjects: 22
Study: 16006842

Group type: EXPERIMENTAL
Intervention: Acticoat
Number of subjects: 47

Group type: COMPARATOR
Intervention: silver sulfadiazine (AgSD)
Number of subjects: 47
Study: 12544993

Group type: EXPERIMENTAL
Intervention: Oligon-treated catheter (polyurethane combined with silver, carbon, and platinum)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Conventional benzalkonium-treated double-lumen central venous catheter
Number of subjects: 545
Study: 10738092

Group type: EXPERIMENTAL
Intervention: PCV
Number of subjects: 123

Group type: COMPARATOR
Intervention: PN23
Number of subjects: 123
Study: 8651107

Group type: EXPERIMENTAL
Intervention: Testosterone alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone with testolactone
Number of subjects: 0
Study: 1725153

Group type: EXPERIMENTAL
Intervention: 400mg aqueous solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: 400mg tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 x 200mg tablets
Number of subjects: 24
Study: 6178151

Group type: EXPERIMENTAL
Intervention: Hapten (10 or 20 ml) before dextran infusion
Number of subjects: 3887

Group type: COMPARATOR
Intervention: Dextran 70 without hapten
Number of subjects: 3887
Study: 30514803

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 422

Group type: COMPARATOR
Intervention: Imatinib 800 mg
Number of subjects: 422
Study: 30146644

Group type: EXPERIMENTAL
Intervention: Tilted dental implantation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Maxillary sinus lifting
Number of subjects: 80
Study: 27532829

Group type: EXPERIMENTAL
Intervention: Obeticholic acid 5-10 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Obeticholic acid 10 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 25418218

Group type: EXPERIMENTAL
Intervention: Human recombinant BNP (rhBNP; 0.005 μg/kg/min)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Isotonic normal saline (NaCl 0.9%, 1 mL/kg/h) for 24 hours before CA or PCI
Number of subjects: 1000
Study: 22854549

Group type: EXPERIMENTAL
Intervention: Yoga-focused prenatal program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 20635771

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) for Panic Disorder
Number of subjects: 0
Study: 18192953

Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (NPs) applied prophylactically, in lower doses, for prolonged duration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (NPs)
Number of subjects: 0
Study: 15293053

Group type: EXPERIMENTAL
Intervention: PACE group (PG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35
Study: 12239065

Group type: EXPERIMENTAL
Intervention: STI‐571 (Gleevec, imatinib mesylate)
Number of subjects: 0
Study: 8084629

Group type: EXPERIMENTAL
Intervention: Nasal hinge techniques
Number of subjects: 100

Group type: COMPARATOR
Intervention: Other lateral crural techniques
Number of subjects: 100
Study: 2913779

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Prazosin, Propranolol, Hydrochlorothiazide (all drug treatment groups)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propranolol and Hydrochlorothiazide
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All active treatment groups
Number of subjects: 69
Study: 64267

Group type: EXPERIMENTAL
Intervention: gestonorone caproate (200 mg daily and 200 mg on alternate days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: cyproterone acetate (300 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: gestonorone caproate on alternate days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 31952493

Group type: EXPERIMENTAL
Intervention: Active TDM (therapeutic drug monitoring) of beta-lactam and fluoroquinolones
Number of subjects: 450

Group type: COMPARATOR
Intervention: Non-TDM (control group)
Number of subjects: 450
Study: 31179489

Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oleic acid diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palmitic acid diet
Number of subjects: 20
Study: 28765006

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Relapse Prevention (MBRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26350273

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg once daily for 12 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo once daily for 12 days
Number of subjects: 24
Study: 23032917

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 47
Study: 22254683

Group type: EXPERIMENTAL
Intervention: Tracking training group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Move group
Number of subjects: 16
Study: 17392700

Group type: EXPERIMENTAL
Intervention: Above-median consumption of sherry and port among individuals with a prior skin cancer history
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Total alcohol intake, beer, white wine, red wine, sherry, and port
Number of subjects: 1360
Study: 16447002

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 156
Study: 12952402

Group type: EXPERIMENTAL
Intervention: Infants interacting with an adult who expressed excitement about a new toy.
Number of subjects: 0
Study: 10708180

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (20 mL of sterile water)
Number of subjects: 10
Study: 15096005

Group type: EXPERIMENTAL
Intervention: Intravenous therapy with continuous IGF‐I (0.01 mg/kg/hour)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard neurosurgical intensive care plus aggressive nutritional support (Control)
Number of subjects: 33
Study: 8455310

Group type: EXPERIMENTAL
Intervention: 10% lipid emulsion with a PL/TG weight ratio of 0.12 (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 10% emulsion with a PL/TG weight ratio of 0.06 (group B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 20% emulsion with a PL/TG weight ratio of 0.06 (group C)
Number of subjects: 18
Study: 3786302

Group type: EXPERIMENTAL
Intervention: Synthetic analog of leu-enkephalin (dalargin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30012385

Group type: EXPERIMENTAL
Intervention: Flavonols (63.36 mg/d)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Flavanols (107.61 mg/d)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Flavanones (40.92 mg/d)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Catechins (63.36 mg/d)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Flavonols and catechins
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Flavanones
Number of subjects: 340
Study: 26970526

Group type: EXPERIMENTAL
Intervention: Tofacitinib XR 11 mg QD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tofacitinib IR 5 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tofacitinib XR 11 mg QD (fed state)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tofacitinib XR 11 mg QD (multiple doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tofacitinib IR 5 mg twice daily (multiple doses)
Number of subjects: 24
Study: 24828848

Group type: EXPERIMENTAL
Intervention: Intravenous dezocine 0.1 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matching placebo (0.9% saline)
Number of subjects: 80
Study: 22092380

Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (CM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Connective tissue autograft (CTG)
Number of subjects: 24
Study: 20194448

Group type: EXPERIMENTAL
Intervention: Rituximab retreatment (2 x 1000 mg IV)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Placebo retreatment
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Rituximab retreatment
Number of subjects: 559
Study: 18611254

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Transthoracic echocardiogram (TTE)
Number of subjects: 31
Study: 15867994

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Transluminal coronary angioplasty (TCA)
Number of subjects: 210
Study: 12740233

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 to 300 mg/d) for 1 to 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11108563

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TUMT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost evaluation
Number of subjects: 0
Study: 8839577

Group type: EXPERIMENTAL
Intervention: Culturally acceptable cervical cancer screening program using Talking Circles
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study: 1624634

Group type: EXPERIMENTAL
Intervention: h-EGF (10 micrograms/mL, applied topically twice a day for up to 10 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (applied topically twice a day for up to 10 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: h-EGF
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 6334524

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (mean dose 0.4 micrograms/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calcium and placebo
Number of subjects: 23
Study: 29372470

Group type: EXPERIMENTAL
Intervention: Topiroxostat (40 to 160 mg/day, administered BID for 28 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (matching placebo administered BID for 28 weeks)
Number of subjects: 65
Study: 27863179

Group type: EXPERIMENTAL
Intervention: Bedaquiline (24 weeks treatment)
Number of subjects: 335
Study: 25358679

Group type: COMPARATOR
Intervention: Antenatal milk expressing starting at 36 weeks gestation, encouraged to express twice daily for 10 min.
Number of subjects: 658

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Antenatal milk expressing intervention.
Number of subjects: 658
Study: 22873719

Group type: EXPERIMENTAL
Intervention: Emotional intelligence training (12 sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no emotional intelligence training)
Number of subjects: 30
Study: 19896655

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with endometriosis
Number of subjects: 38

Group type: COMPARATOR
Intervention: Peritoneal fluid from nonendometriosis patients (control)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Human tubal fluid (HTF) media
Number of subjects: 38
Study: 19227901

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 3 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (no inhibitors of GMG-CoA-reductase)
Number of subjects: 165
Study: 15895898

Group type: EXPERIMENTAL
Intervention: SINGLE therapy (initially sulfasalazine with or without prednisolone)
Number of subjects: 157

Group type: COMPARATOR
Intervention: COMBI therapy (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: sIL‐2R <442 U/ml
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: sIL‐2R level
Number of subjects: 157
Study: 12195121

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11233145

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba leaf extract (GBLE)
Number of subjects: 0
Study: 7598110

Group type: EXPERIMENTAL
Intervention: FR-4 appliance and lip-seal training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 2205128

Group type: EXPERIMENTAL
Intervention: 6 mg naltrexone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 3 mg naltrexone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 433996

Group type: EXPERIMENTAL
Intervention: Intermittent clamping regimen (started on the first postoperative day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Constant open drainage
Number of subjects: 87
Study: 29921504

Group type: EXPERIMENTAL
Intervention: Training group (90 trials of three balance tasks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Participants with high lower limb power
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Participants with low lower limb power
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no prior practice)
Number of subjects: 32
Study: 28034612

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Information page intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Video control
Number of subjects: 152

Group type: COMPARATOR
Intervention: Information page control
Number of subjects: 152
Study: 25893514

Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Latanoprost 0.005% + benzalkonium chloride 0.02%
Number of subjects: 40
Study: 23727387

Group type: EXPERIMENTAL
Intervention: Apomorphine (1.5 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 21820539

Group type: EXPERIMENTAL
Intervention: Weekly musculoskeletal treatment for 6 weeks in addition to normal optimal physiotherapy care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal optimal physiotherapy care
Number of subjects: 20
Study: 19304565

Group type: EXPERIMENTAL
Intervention: 10 minutes of chest percussion at noon
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no chest percussion)
Number of subjects: 28
Study: 17077730

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15095516

Group type: EXPERIMENTAL
Intervention: Pharmacist-led diabetes management program with low-literacy-oriented interventions
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Low literacy patients
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: High literacy patients
Number of subjects: 159
Study: 11573528

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg kg(‐1) at induction followed by continuous infusion of 3 mg kg(‐1) over 24 h (pre ketoprofen group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg kg(‐1) after surgery followed by continuous infusion of 3 mg kg(‐1) over 24 h (post ketoprofen group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Normal saline (placebo group)
Number of subjects: 106
Study: 9661740

Group type: EXPERIMENTAL
Intervention: 400 mg/day of carbamazepine (CBZ)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 800 mg/day of valproic acid (VPA)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 400 mg/day of carbamazepine (CBZ) and 800 mg/day of valproic acid (VPA)
Number of subjects: 3
Study: 8151854

Group type: EXPERIMENTAL
Intervention: Steam treatment (40 L/min of heated saturated air at 43 degrees C for 60 minutes)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo group (2 L/min of ambient air at 20 degrees C to 24 degrees C)
Number of subjects: 68
Study: 3219316

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg body-weight per day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.45 g/kg body-weight per day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg body-weight per day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.75 g/kg body-weight per day
Number of subjects: 15
Study: 31694237

Group type: EXPERIMENTAL
Intervention: Combined training (n = 17, 20 minutes of strength exercises at 50‐60% 1RM and 25 minutes of endurance training at 60‐80% HRmax)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Endurance training (n = 22, 60‐80% HRmax)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both training programs
Number of subjects: 39
Study: 28840615

Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phospholipidated Curcumin (1 g/day, containing 200 mg of pure curcumin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (1 g/day)
Number of subjects: 120
Study: 26057939

Group type: EXPERIMENTAL
Intervention: Aspirin supplementation (acute and chronic)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23937271

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg plus mirodenafil 50 mg (group B)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Dapoxetine 30 mg plus placebo (group A)
Number of subjects: 118
Study: 21803422

Group type: EXPERIMENTAL
Intervention: 5 mg linagliptin after an overnight fast of at least 10 hours
Number of subjects: 32

Group type: COMPARATOR
Intervention: 5 mg linagliptin after ingestion of a high-fat, high-calorie breakfast
Number of subjects: 32
Study: 19781210

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/qn)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no atorvastatin)
Number of subjects: 120
Study: 16487269

Group type: EXPERIMENTAL
Intervention: GNB3 C825T polymorphism
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Presence of the T allele in obese population
Number of subjects: 1568
Study: 15462686

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Diclofenac sodium 100 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 11562389

Group type: EXPERIMENTAL
Intervention: Laser-induced fluorescence endoscopy (LIFE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional white-light bronchoscopy (WLB)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined LIFE and WLB
Number of subjects: 55
Study: 9576201

Group type: EXPERIMENTAL
Intervention: alpha2b-IFN (Intron-A) maintenance therapy
Number of subjects: 284

Group type: COMPARATOR
Intervention: no maintenance therapy
Number of subjects: 284
Study: 7936018

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Discontinuation of azathioprine
Number of subjects: 16
Study: 2953770

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracoronary streptokinase/placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo/intracoronary streptokinase
Number of subjects: 100
Study: 29607480

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 143

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 143
Study: 26886406

Group type: EXPERIMENTAL
Intervention: Usual care augmented by virtual house calls with a Parkinson's disease specialist (4 virtual visits over 1 year via secure, Web‐based videoconferencing)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 210
Study: 24771805

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride)
Number of subjects: 44
Study: 23512329

Group type: EXPERIMENTAL
Intervention: p114RhoGEF expression in squamous-cell lung carcinoma
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: p114RhoGEF expression
Number of subjects: 105